- Trial phase
- Approved
- Time to market
- Already approved and marketed in the US (since 2020) and EU (since 2021). The EU label expansion for three pediatric indications is pending European Commission decision, expected before year-end 2026.
- Why 3/10
- Sogroya is already approved and commercialized in both the US and EU. The next catalyst is the European Commission's decision on three new pediatric indications (ISS, SGA, Noonan syndrome), expected before year-end 2026. However, Sogroya is a very small part of Novo Nordisk's massive GLP-1-driven business, so even a positive decision will not materially move NVO shares.
The next catalyst is the European Commission's decision on Sogroya's three new pediatric indications (ISS, SGA, Noonan syndrome), expected before year-end 2026. The CHMP has already issued a positive opinion after re-examination, so approval is widely expected. Given Sogroya's small contribution to Novo Nordisk's total revenue (combined Norditropin/Sogroya sales were ~DKK 6B in 2025 vs. total revenue of ~DKK 309B), even a positive decision is unlikely to move NVO shares materially.
Price Chart
Executive Summary
Sogroya (somapacitan-beco) is Novo Nordisk's once-weekly long-acting growth hormone analogue, first approved by the FDA in August 2020 for adult growth hormone deficiency and expanded to pediatric GHD in April 2023. In February 2026, the FDA approved three additional pediatric indications: idiopathic short stature (ISS), small for gestational age (SGA), and Noonan syndrome. In the EU, the CHMP has recommended the same three pediatric indications after re-examination, with a European Commission decision expected before year-end 2026. Combined Norditropin and Sogroya sales reached approximately DKK 6 billion in 2025, but Sogroya represents a very small fraction of Novo Nordisk's total revenue (~DKK 309B in 2025), which is overwhelmingly driven by GLP-1 diabetes and obesity drugs.
How It Works
Sogroya is a lab-engineered version of human growth hormone, modified to last longer in the body by hitching a ride on a blood protein called albumin. This allows patients to receive one injection per week instead of daily shots, reducing the treatment burden for growth hormone deficiency and related growth disorders.
Trial Status
Sogroya is FDA-approved for adult GHD (2020), pediatric GHD (2023), and three additional pediatric indications (ISS, SGA, Noonan syndrome, February 2026). The pivotal Phase 3 REAL8 basket trial demonstrated non-inferiority to daily growth hormone across multiple pediatric growth disorders at 52 weeks, with sustained efficacy and safety through two years. A seven-year follow-up (REAL3 trial) confirmed sustained safety and efficacy.
The Two-Sided Case
Upcoming Catalysts
- European Commission decision on three new pediatric indications (ISS, SGA, Noonan syndrome) - expected before year-end 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S 6-K NVO ·Originating report